Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID M HUFNAGEL

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1780674036
CMS profile
262672
Location
EUGENE, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$198.29

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $198.29 9

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $82.93 3
Amgen Inc. $24.60 1
TESARO, Inc. $23.34 1
Novartis Pharmaceuticals Corporation $20.48 1
Merck Sharp & Dohme Corporation $18.61 1
Exelixis Inc. $14.61 1
Incyte Corporation $13.72 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID M HUFNAGEL

NPI 1780674036 · CMS profile ID 262672

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

EUGENE, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780674036?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID M HUFNAGEL, NPI 1780674036, CMS profile ID 262672. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780674036?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DAVID M HUFNAGEL, NPI 1780674036, CMS profile ID 262672. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780674036?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DAVID M HUFNAGEL, NPI 1780674036, CMS profile ID 262672, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1780674036?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $198.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $38.1610/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658490905 CMS
Janssen Biotech, Inc. $21.8309/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658490903 CMS
Novartis Pharmaceuticals Corporation $20.4807/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659584297 CMS
TESARO, Inc. $23.3404/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675561551 CMS
Merck Sharp & Dohme Corporation $18.6103/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695363555 CMS
Janssen Biotech, Inc. $22.9402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658490899 CMS
Amgen Inc. $24.6001/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662287681 CMS
Exelixis Inc. $14.6101/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686547349 CMS
Incyte Corporation $13.7201/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666277111 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $198.29 9
PY2020 $22.74 2
PY2022 $13.61 1
PY2023 $94.25 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $435.09 1
PY2022 Principal investigator $149.79 1
PY2021 Principal investigator $2,779.87 1
PY2020 Principal investigator $65,458.72 13
PY2019 Principal investigator $45,905.14 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,000.00 12/16/2020 Covered Recipient Teaching Hospital
Good Samaritan Hospital Corvallis
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744283093
Principal investigator 1 Incyte Corporation $2,515.50 11/11/2020 Covered Recipient Teaching Hospital
Good Samaritan Hospital Corvallis
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744283061
Principal investigator 1 Incyte Corporation $520.00 11/11/2020 Covered Recipient Teaching Hospital
Good Samaritan Hospital Corvallis
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744283063
Principal investigator 1 Incyte Corporation $105.00 11/11/2020 Covered Recipient Teaching Hospital
Good Samaritan Hospital Corvallis
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744283065
Principal investigator 1 Incyte Corporation $243.00 11/11/2020 Covered Recipient Teaching Hospital
Good Samaritan Hospital Corvallis
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744283067
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 08/03/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 No dispute reported 06/30/2026 740755993
Principal investigator 1 Merck Sharp & Dohme Corporation $657.65 07/20/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 No dispute reported 06/30/2026 740755989
Principal investigator 1 Merck Sharp & Dohme Corporation $38.35 05/11/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 No dispute reported 06/30/2026 740755985
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 05/01/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 No dispute reported 06/30/2026 740755991
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $110.00 04/28/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA No dispute reported 06/30/2026 749644965
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $2,300.00 04/28/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA No dispute reported 06/30/2026 749645135
Principal investigator 1 Merck Sharp & Dohme Corporation $382.30 04/20/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 No dispute reported 06/30/2026 740755987
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $5,475.00 01/16/2020 Covered Recipient Teaching Hospital
GOOD SAMARITAN HOSPITAL CORVALLIS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NERATINIB (HKI-272) AFTER TRASTUZUMAB IN WOMEN WITH EARLY-STAGE HER-2/NEU OVEREXPRESSED/AMPLIFIED BREAST CANCER No dispute reported 06/30/2026 749644735